Drug Trial Radar · NCT00903981
Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Avanafil
Last checked: Nov 20, 2026Latest source record: Apr 23, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
208
Actual
Start
Mar 2009
Primary completion
Oct 2009
Study completion Nov 2009
Sponsor
- Lead sponsor
- JW PharmaceuticalIndustry
- Sponsor type
- Industry
- First posted
- May 19, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Male only, from 19 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to confirm the efficacy and the safety of Avanafil 100mg, 200mg or placebo administered orally for 12 weeks in patients with erectile dysfunction. The efficacy is evaluated by IIEF, SEP Q2 and Q3 and GEAQ and the safety is evaluated by laboratory tests, vital signs, physical examination and adverse events.
Conditions
- Erectile Dysfunction
Interventions
AvanafilDrug
2 tablets(Avanafil 100mg tablet + Placebo 200mg tablet), 30 minutes before sexual intercourse
AvanafilDrug
2 Tablets(Avanafil 200mg tablet + Placebo 100mg tablet), 30 minutes before sexual intercourse
PlaceboDrug
2 Tablets(Placebo 100mg tablet + Placebo 200mg tablet), 30 minutes before sexual intercourse
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change of EF domain score in the IIEF(The International Index of Erectile Function)Time frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chonbuk national university hospital
Jeonju, Cholabukdo, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.